These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 20160157)

  • 21. The dipeptidyl peptidase-4 inhibitor linagliptin exhibits time- and dose-dependent localization in kidney, liver, and intestine after intravenous dosing: results from high resolution autoradiography in rats.
    Greischel A; Binder R; Baierl J
    Drug Metab Dispos; 2010 Sep; 38(9):1443-8. PubMed ID: 20538719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus.
    Friedrich C; Glund S; Lionetti D; Kissling CJ; Righetti J; Patel S; Graefe-Mody U; Retlich S; Woerle HJ
    Br J Clin Pharmacol; 2013 Sep; 76(3):445-54. PubMed ID: 23331248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Linagliptin (Tradjenta)--a new DPP-4 inhibitor for type 2 diabetes.
    Med Lett Drugs Ther; 2011 Jun; 53(1367):49-50. PubMed ID: 21701440
    [No Abstract]   [Full Text] [Related]  

  • 24. Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes.
    Friedrich C; Emser A; Woerle HJ; Graefe-Mody U
    Am J Ther; 2013; 20(6):618-21. PubMed ID: 23411609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Toth PP
    Postgrad Med; 2011 Jul; 123(4):46-53. PubMed ID: 21680988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incorporating Pharmacological Target-Mediated Drug Disposition (TMDD) in a Whole-Body Physiologically Based Pharmacokinetic (PBPK) Model of Linagliptin in Rat and Scale-up to Human.
    Wu N; An G
    AAPS J; 2020 Sep; 22(6):125. PubMed ID: 32996028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Physiologically Based Pharmacokinetic Model of the DPP-4 Inhibitor Linagliptin to Describe its Nonlinear Pharmacokinetics in Humans.
    Sarashina A; Chiba K; Tatami S; Kato Y
    J Pharm Sci; 2020 Jul; 109(7):2336-2344. PubMed ID: 32283067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects.
    Graefe-Mody U; Giessmann T; Ring A; Iovino M; Woerle HJ
    Clin Ther; 2011 Aug; 33(8):1096-103. PubMed ID: 21803422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin.
    Grunberger G
    Postgrad Med; 2013 May; 125(3):79-90. PubMed ID: 23748509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.
    Golightly LK; Drayna CC; McDermott MT
    Clin Pharmacokinet; 2012 Aug; 51(8):501-14. PubMed ID: 22686547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):363-77. PubMed ID: 23373842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2012 Feb; 67(2):91-7. PubMed ID: 22482239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioequivalence of Linagliptin 5 mg once daily and 2.5 mg twice daily: pharmacokinetics and pharmacodynamics in an open-label crossover trial.
    Friedrich C; Jungnik A; Retlich S; Ring A; Meinicke T
    Drug Res (Stuttg); 2014 May; 64(5):269-75. PubMed ID: 24154935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans.
    Blech S; Ludwig-Schwellinger E; Gräfe-Mody EU; Withopf B; Wagner K
    Drug Metab Dispos; 2010 Apr; 38(4):667-78. PubMed ID: 20086031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers.
    Friedrich C; Shi X; Zeng P; Ring A; Woerle HJ; Patel S
    Int J Clin Pharmacol Ther; 2012 Dec; 50(12):889-95. PubMed ID: 23073142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of linagliptin in subjects with hepatic impairment.
    Graefe-Mody U; Rose P; Retlich S; Ring A; Waldhauser L; Cinca R; Woerle HJ
    Br J Clin Pharmacol; 2012 Jul; 74(1):75-85. PubMed ID: 22242621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans.
    Fuchs H; Tillement JP; Urien S; Greischel A; Roth W
    J Pharm Pharmacol; 2009 Jan; 61(1):55-62. PubMed ID: 19126297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.
    Thomas L; Eckhardt M; Langkopf E; Tadayyon M; Himmelsbach F; Mark M
    J Pharmacol Exp Ther; 2008 Apr; 325(1):175-82. PubMed ID: 18223196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharmacological and clinical profiles of the DPP-4 inhibitor linagliptin (Trazenta)].
    Ohmura T; Hayashi N; Encinas J
    Nihon Yakurigaku Zasshi; 2012 Apr; 139(4):174-83. PubMed ID: 22498683
    [No Abstract]   [Full Text] [Related]  

  • 40. Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects.
    Graefe-Mody U; Rose P; Ring A; Zander K; Iovino M; Woerle HJ
    Drug Metab Pharmacokinet; 2011; 26(2):123-9. PubMed ID: 21084763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.